Brief: Iterum Therapeutics Says Resubmission Of NDA For Oral Sulopenem To US FDA Is On Track For First Half Of Q2 2024
06/03/2024 13:10
March 6 (Reuters) - Iterum Therapeutics Plc ITRM.O :
* ITERUM THERAPEUTICS PROVIDES BUSINESS UPDATE
* RESUBMISSION OF NDA IS ON TRACK FOR FIRST HALF OF Q2 24
* EXTENDED CASH RUNWAY INTO 2025
Source text for Eikon: ID:nGNX9k3Hst
Further company coverage: ITRM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Iterum Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Entergy, US natgas stocks, Brown-Forman, Datacentrex
U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Iterum Therapeutics plummets after filing wind up petition
Iterum seeks court-led dissolution amid cash crisis, inability to raise funds (updated)
Iterum files wind-up petition due to limited cash, inability to raise equity